Abstract: A kit includes a mesh substrate and a polymer that is fixed to the mesh substrate. The polymer includes an active agent that is configured to elute over time. The kit further includes a hemostatic agent. The hemostatic agent is separate from the mesh substrate and the polymer. Systems and methods are disclosed.

Abstract: A medical device, a method for preparation thereof, and use thereof are provided. The medical device comprises a thermoplastic elastomer that is composed of soft segments and hard segments. The method for preparing a medical device comprising a thermoplastic elastomer, comprises forming the thermoplastic elastomer into tubing or other shapes via extrusion, molding, or coating, assembling the tubing or other shapes with other parts including: cables, coils, coated cables, or coated coils, and bonding the tubing, cables, or coils with other components including: other tubing components, cables, coils, sleeves, electrical pulse generator, defibrillation shock generator, electrodes, sensors, or drug release components. The medical device is used for correcting cardiac rhythm, defibrillating, assisting hearts, sensing, stimulating neurological systems, gastrointestinal system, or skeletomuscular tissues or organs.

Abstract: Disclosed is a segmented thermoplastic elastomer that can be a polyurethane, polyurea, or polyurethane-urea comprising soft segments and hard segments, wherein the soft segments are made of polyolefin diols or polyolefin diamine that may have 0 to 1000 carbon atoms in the main chain, wherein each carbon atom in the main chain may have 0 to 2 side chains and each side chain may have 0 to 30 carbon atoms, the hard segment is made of a diisocyante and a chain extender, the hard segments make up 10-60% of the elastomer and the soft segments make up the rest, the number-average molecular weight of the elastomer is 5×103-1000×103 g/mol, the ultimate elongation of the elastomer is 100-1000%, the Young's modulus is 1 to 3,000 MPa, and the ultimate tensile strength is 10-100 MPa. Also disclosed are a method for preparing the segmented thermoplastic elastomer and use of segmented thermoplastic elastomer.

Abstract: A method for preparing diphenol compounds includes adding a hydroxyphenyl carboxylic acid, a tyrosine ethyl ester, hydroxybenzotriazole hydrate and a solvent and stirring to produce a first solution. EDCl HCl is added to the first solution to produce a first mixture. Ethyl acetate is added to the first mixture to produce a second mixture. The second mixture is added to sodium chloride to produce a third mixture having layer separation. An aqueous layer is removed from the third mixture. The third mixture is extracted with reagents after the aqueous layer has been removed from the third mixture to produce a fourth mixture. Magnesium sulfate is added to the fourth mixture to produce a fifth mixture. The fifth mixture is filtered to produce filtrate. The filtrate is concentrated. Crystallization of the concentrated filtrate is induced. Methylene chloride is added to the crystallized filtrate to produce a solid product.

Abstract: A method for hydrogenating tyrosine derived polyarylates includes dissolving a second polyarylate with DMF in a flask to produce a first solution. A catalyst is added to the first solution to produce a polymer solution. The polymer solution is filtered through a Celite bed to produce a filtrate. The filtrate is added to water and stirred to precipitate the polyarylate.

Abstract: A method for preparing tyrosine derived polyarylates includes combining a desaminotyrosyl-tyrosine ethyl ester, a desaminotyrosyl-tyrosine benzylester, succinic acid and a catalyst in a flask to produce a first mixture. Methylene chloride is added to the first mixture to produce a first suspension. Diisopropylcarbodiimide (DIPC) is added to the first mixture to produce a first solution. The first solution is added to a non-solvent to produce a precipitate. The precipitate is dissolved in methylene chloride to form a polymer solution. The polymer solution is blended with a slurry to produce polymer shreds. The polymer shreds are blended with a second slurry to produce a tyrosine derived polyarylate.

Abstract: A kit includes a mesh substrate and a polymer that is fixed to the mesh substrate. The polymer includes an active agent that is configured to elute over time. The kit further includes a hemostatic agent. The hemostatic agent is separate from the mesh substrate and the polymer. Systems and methods are disclosed.

Abstract: A kit includes a mesh substrate and a polymer that is fixed to the mesh substrate. The polymer includes an active agent that is configured to elute over time. The kit further includes a hemostatic agent. The hemostatic agent is separate from the mesh substrate and the polymer. Systems and methods are disclosed.

Abstract: A kit includes a mesh substrate and a polymer that is fixed to the mesh substrate. The polymer includes an active agent that is configured to elute over time. The kit further includes a hemostatic agent. The hemostatic agent is separate from the mesh substrate and the polymer. Systems and methods are disclosed.

Abstract: A composition, article, and method for increasing the hydrolytic stability of a polymer; wherein a composition includes: a polymer comprising functional groups having hydrolyzable bonds; a carbodiimide compound; and a weak base (or hindered amine); wherein the carbodiimide compound and weak base (or hindered amine) are used in amounts effective to decrease the rate and/or extent of hydrolyic degradation of the polymer relative to either used alone in the same amount with the polymer.

Abstract: The invention generally relates to zwitterionic polymers (including zwitterionic copolymers), such as polymethacrylic structures, with pendent functional moieties, such as therapeutic or biologic moieties. More particularly, the invention relates to phosphorylcholine-substituted methacrylic polymers prepared by free radical polymerization and click chemistry, for example, and compositions and products comprising same, as well as related methods and uses of the compositions, for example, as biological or therapeutic agents and in drug delivery thereof.

Abstract: The invention generally relates to zwitterionic polymers (including zwitterionic copolymers), such as polymethacrylic structures, with pendent functional moieties, such as therapeutic or biologic moieties. More particularly, the invention relates to phosphorylcholine-substituted methacrylic polymers prepared by free radical polymerization and click chemistry, for example, and compositions and products comprising same, as well as related methods and uses of the compositions, for example, as biological or therapeutic agents and in drug delivery thereof.

Abstract: Medical leads, such as medical electrical leads and medical neurological leads, that include a polymeric material that includes a silicone-urethane-containing polymer having improved hydrolytic stability.

Abstract: Medical leads, such as medical electrical leads and medical neurological leads, that include a polymeric material that includes a silicone-urethane-containing polymer having improved hydrolytic stability.

Abstract: Medical leads, such as medical electrical leads and medical neurological leads, that include a polymeric material that includes a silicone-urethane-containing polymer having improved hydrolytic stability.

Abstract: The invention generally relates to zwitterionic polymers (including zwitterionic copolymers), such as polymethacrylic structures, with pendent functional moieties, such as therapeutic or biologic moieties. More particularly, the invention relates to phosphorylcholine-substituted methacrylic polymers prepared by free radical polymerization and click chemistry, for example, and compositions and products comprising same, as well as related methods and uses of the compositions, for example, as biological or therapeutic agents and in drug delivery thereof.